Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder

Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Aug 22, 2024

Keywords

ClinConnect Summary

Repetitive Transcranial Magnetic Stimulation (rTMS) is an effective treatment for Major Depressive Disorder (MDD), but response rates are highly variable across individuals. Clinical improvement with rTMS is believed to reflect engagement of a target mood-regulating circuit. This innovative study aims to enhance target circuit engagement through stimulation at an individual's optimal resonant frequency (RF). Circuit connectivity is maintained by oscillations at one or more RFs specific to that circuit for that individual. Personalizing stimulation frequency is an opportunity to optimize rep...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All subjects must be between 21-75 years of age.
• • Must have confirmed diagnosis of severe \*Major Depressive Disorder (single or recurrent episode) as confirmed by the Mini-International Neuropsychiatric Interview (MINI) or/and a score of 17 or above on the Hamilton Depression Rating Scale (HAMD).
• • Failure to respond to a minimum of 2 trials of antidepressant medication.
• • Failure to respond from at least two different agent classes.
• • Accompanied by at least two evidence-based augmentation therapies (Benzodiazepines do not count).
• • Must have a trial of psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration.
• • Subjects are willing and able to adhere to the treatment schedule and required study visits.
• • TMS treatment is clinically-approved only for those suffering from Major Depressive Disorder as their primary diagnosis.
• Exclusion Criteria:
• • Are mentally or legally incapacitated, unable to give informed consent
• • Have an infection or poor skin condition over the scalp where the device will be positioned.
• • Have increased risk of seizure because of family history, stroke, or currently use medications that lead to increased risk for seizure.
• • Diagnosis of acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode.
• • Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system.
• • Presence of an implanted magnetic-sensitive medical device present in the body scan, located less than or equal to 30 centimeters from the transcranial magnetic stimulation magnetic coil or other implanted metal items, including but not limited to a cochlear implant, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents. (Note: Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with transcranial magnetic stimulation and MRI.)
• • Current diagnosis of substance use disorder.